The History of ACE Inhibitors in Scleroderma Renal Crisis

Ruth Jessen Hickman, MD, is a graduate of the Indiana University School of Medicine. She is a freelance medical and science writer living in Bloomington, Ind.

References

1. Bourne FM, Howell DA, Root HS. Renal and cerebral scleroderma. Can Med Assoc J. 1960 Apr 23;82(17):881–886.
2. Moore HC, Sheehan HL. The kidney of scleroderma. Lancet. 1952 Jan 12;1(6698):68–70.
3. Richardson JA. Hemodialysis and kidney transplantation for renal failure from scleroderma. Arthritis Rheum. 1973 Mar-Apr;16(2):265–271.
4. Cannon PJ, Hassar M, Case DB, et al. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore). 1974 Jan;53(1):1–46. 
5. Moorthy AV, Wu MJ, Beirne GJ, et al. Control of hypertension with acute renal failure in scleroderma without nephrectomy. Lancet. 1978 Mar11;1(8063):563–564. 
6. Lopez-Ovejero JA, Saal SD, D’Angelo WA, et al. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med. 1979 Jun 21;300(25):1417–1419.
7. Bryan J. From snake venom to ACE inhibitor—the discovery and rise of captopril. Pharmaceutical Journal. 17 April 2009.
8. Sealey JE. John H. Laragh, MD: Clinician-scientist. Am J Hypertens. 2014 Aug;27(8):1019–1023.
9. Zawada ET Jr, Clements PJ, Furst DA, et al. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron. 1981;27(2):74–78.
10. Whitman HH 3rd, Case DB, Laragh JH, et al. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum. 1982 Mar;25(3):241–248.
11. Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990 Sep 1;113(5):352–357.
12. Woodworth TG, Suliman YA, Li W, et al. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016 Nov;12(11):678–691. 
13. Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev. 2018 Sep;17(9):882–889.
14. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000 Oct 17;133(8):600–603.
15. Steen VD. Kidney involvement in systemic sclerosis. Presse Med. 2014 Oct;43(10 Pt 2):e305–314.
16. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007 Jul;66(7):940–944. 
17. Penn H, Quillinan N, Khan K, et al. Targeting the endothelin axis in scleroderma renal crisis: Rationale and feasibility. QJM. 2013 Sep;106(9):839–848.